LAMB

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Antimalarial medication, Research, FURI, Congress, Conference, Biotechnology, TIMM, Aspergillosis, GSK, Sale, Mucorales, LAMB, National Institutes of Health, NIH, Trial of the century, IND, AAAM, Investment, Data analysis, Medical Mycology, Pharmaceutical industry

“SCY-247 continues to demonstrate highly encouraging preclinical results, with potent activity against a broad range of fungal pathogens, including mucormycosis.

Key Points: 
  • “SCY-247 continues to demonstrate highly encouraging preclinical results, with potent activity against a broad range of fungal pathogens, including mucormycosis.
  • In March 2023, SCYNEXIS and GSK entered into an exclusive license agreement for the development, manufacturing and commercialization of ibrexafungerp (BREXAFEMME).
  • Presented preclinical data on SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) held in Athens, Greece October 20-23, 2023.
  • Cash, cash equivalents and investments totaled $98.0 million on December 31, 2023, compared to $73.5 million on December 31, 2022.

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Retrieved on: 
Monday, January 29, 2024
Mortality, Patient, Leukemia, LAMB, Therapy, MD, FCCP, Infection, Biotechnology, Survival, Fungal infection, COVID, FAAM, Aspergillosis, Division, Immunodeficiency, Conference, Bone marrow, UCLA, Transplant, B♭ (musical note), Doctor of Philosophy, Antimalarial medication, FIDSA, Harbor–UCLA Medical Center, Lung, AAAM, Diabetes, Pharmaceutical industry

In this highly lethal mouse model of mucormycosis, SCY-247 showed very promising in vivo efficacy.

Key Points: 
  • In this highly lethal mouse model of mucormycosis, SCY-247 showed very promising in vivo efficacy.
  • This is comparable to the 40% survival observed in the control group treated with 10 mg/kg of intravenous standard of care of liposomal amphotericin B (LAMB) (p = 0.008 vs. placebo).
  • The combination treatment of SCY-247 plus LAMB demonstrated the greatest reduction in fungal burden and was highly statistically significant in both lung and brain tissue (both p
  • “These positive data continue to accumulate and define the unique properties of SCY-247, highlighting its potential to be differentiated from currently available antifungals.

Calix Delivers End-to-End Network Automation for Operations, Reducing Turnup Times Up to 67 Percent To Fuel Rapid Growth for Broadband Businesses at the Lowest Possible OPEX

Retrieved on: 
Tuesday, February 21, 2023
Data Management, Security, Technology, Software, Networks, Artificial Intelligence, Internet, Cloud, Human, System, History of science and technology, NYSE, LAMB, Maintenance, Automation, ONT, PON, Calix, Inc., OPEX, OLT, Health, Mobile phone, Sales, Calix

By leveraging Calix Operations Cloud (Operations Cloud), broadband operations teams can apply workflow automation, machine learning-based insights, configurable network health thresholds, and automated alarm management across the entire subscriber-facing network.

Key Points: 
  • By leveraging Calix Operations Cloud (Operations Cloud), broadband operations teams can apply workflow automation, machine learning-based insights, configurable network health thresholds, and automated alarm management across the entire subscriber-facing network.
  • This new automation transforms how operations teams handle reporting, notifications, alarms, and monitoring for network performance and health.
  • By leveraging the powerful new automation features on the Calix platform, BSPs can:
    Streamline new network services and SmartLife managed services turnup.
  • Increased automation on the Calix platform enables operations teams to streamline workflows and automate network health monitoring and troubleshooting.

Sterling LAMB Wins the Calix Customer Innovations “Giant of Operations” Award for Its Innovative Use of Calix Platforms To Reduce Managed Services Provisioning Times by 67 Percent

Retrieved on: 
Wednesday, December 14, 2022
Apps, Applications, Technology, Telecommunications, Software, Networks, Internet, Hardware, Cloud, Giant, Support, Ecosystem, Revenue, Annual report, NYSE, Family, Intelligence, LAMB, OPEX, Form 10-Q, Marketing, Growth, Data-rate units, Sterling, Acquisition, Internet service provider, Operation, Calix

Calix, Inc. (NYSE: CALX) recognizes Sterling Local Area Municipal Broadband (Sterling LAMB) as a Giant of Operations and a 2022 Calix Customer Innovations Award winner.

Key Points: 
  • Calix, Inc. (NYSE: CALX) recognizes Sterling Local Area Municipal Broadband (Sterling LAMB) as a Giant of Operations and a 2022 Calix Customer Innovations Award winner.
  • Announced at Calix ConneXions 2022, the award honors Sterling LAMB for using Calix platforms Calix Intelligent Access EDGE , Calix Revenue EDGE , and Calix Cloudto deliver the exciting managed services subscribers demand.
  • Underscoring their innovative approach to operations, Sterling LAMB leverages Calix Operations Cloud (Operations Cloud) to quickly turn up value-added subscriber services.
  • Additionally, Sterling LAMB has used Calix Premier Customer Success Services to scale the expertise of their team and get optimal results from their investment in Calix platforms.

SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
Infection, Auris, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Survival, EDT, Posaconazole, POSA, Candida auris, Fluconazole, Patient, NASDAQ, Drug of last resort, European, IV, Prescription, Data, BID, FDA, Mycosis, Mouse, Recurrence, Commercial, Biotechnology, FURI, Congress, NDA, LAMB, Tablet, Candidiasis, Headache, Mucormycosis, Fungemia, HCPS, GLOBE, Pharmaceutical industry, Insurance, Medical device, IQVIA, VVC

SCYNEXIS will host a conference call today, May 12 at 8:30 a.m. EDT

Key Points: 
  • SCYNEXIS will host a conference call today, May 12 at 8:30 a.m. EDT
    JERSEY CITY, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended on March 31, 2022.
  • Research and development expense for the first quarter of 2022 decreased to $5.7 million from $6.9 million versus the first quarter of 2021.
  • Selling, general & administrative (SG&A) expense for the first quarter of 2022 increased to $14.6 million from $6.7 million versus the first quarter of 2021.
  • Total other income was $9.6 million for the first quarter of 2022, versus total other expense of $2.0 million for the first quarter of 2021.

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
Wednesday, April 27, 2022
Patient, Treatment, Biotechnology, COVID-19, Mucormycosis, NASDAQ, Research, European, Infection, LAMB, GLOBE, POSA, Drug of last resort, Mortality, Congress, FURI, Candida auris, Fungemia, Auris, HIV disease progression rates, Disease, Posaconazole, Mycosis, Interim, Survival, Pharmaceutical industry, Medical imaging

The posters were presented at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held in Lisbon, Portugal April 23-26, 2022.

Key Points: 
  • The posters were presented at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held in Lisbon, Portugal April 23-26, 2022.
  • We are excited to share these latest data with the medical community as we advance our hospital clinical programs in invasive candidiasis, including candidemia, said David Angulo, M.D.
  • Ibrexafungerp is in late-stage investigation and development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • In addition, late-stage clinical investigation of oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.